Clinical trial of Etanercept for Wegener’s disease shows no benefit

A Johns Hopkins-led study designed to evaluate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to show any benefit. Etanercept, also called Enbrel, is a common treatment for rheumatoid arthritis and other types of joint inflammation.

“We had hoped that this approach to the treatment of Wegener’s granulomatosis would be useful in preventing disease relapses,” says John H. Stone, M.D., associate professor of medicine, director of the Johns Hopkins Vasculitis Center, and lead investigator of the study published in the Jan. 27, 2005, issue of the New England Journal of Medicine.

The rest of this article is here.

In short, Etanercept does not work for WG patients.

My Analysis: Research is good in finding what works for chronic illness. Too bad that this medication will not help WG patients. However, it is another step towards some medication that can help us.

Advertisements

About Cyn Bagley

My life is a mixture of travel, jobs, and disease. You can find some of my novels on amazon.com under the name Cyn Bagley.
This entry was posted in Medication, research. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s